Review of cyclosporine immunosuppressive safety data in dermatology patients after two decades of use.
Cyclosporine is an immunosuppressive agent that has been shown to be effective in the treatment of psoriasis. However, its serious side effects in transplant patients have hindered many dermatologists from exploiting its therapeutic capabilities. The literature contains reports of lymphomas, internal malignancies, skin cancers, and serious infections in psoriasis patients on cyclosporine therapy. However, no study has evaluated the relative risk of these side effects in relation to the general population, nor monitored the patients for years after cyclosporine was discontinued. The recently published 5-year cohort study is the most rigorous data to date on the long-term safety of cyclosporine and shows no increased risk of lymphoma or internal malignancies. The study, however, illustrates increased risk of non-melanoma skin cancers, especially squamous cell carcinoma. Review of the literature does not suggest any increased risk of opportunistic infections or tuberculosis reactivation. These data suggest that cyclosporine in dermatologic dosage (3-5 mg/kg/d) is safe and dermatologists may consider using it.
Behnam
Shahrad M
SM
Oregon Health Sciences and University School of Medicine, Portland, OR, USA.
Behnam
Shahdad E
SE
Koo
John Y
JY
D015331:Cohort Studies; D016572:Cyclosporine / Q000009:adverse effects*; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects*; D008223:Lymphoma / Q000139:chemically induced; D011701:PUVA Therapy / Q000009:adverse effects; D011565:Psoriasis / Q000188:drug therapy*; D012306:Risk; D012878:Skin Neoplasms / Q000139:chemically induced
D007166:Immunosuppressive Agents; D016572:Cyclosporine